The contents of this website are intended for US healthcare professionals only.
Indication
RYSTIGGO (rozanolixizumab-noli) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Please enter your email.
Your password will be reset and a temporary password will be sent to the email address on file.
